Clinical studies conducted by our team on GBM patients (n = 319) have demonstrated that IA administration has the potential to extend the overall median survival to 25 months [ 8 ], which is quite significant compared to the current standard of care first-line treatment (overall median survival: 14.6 months) [ 1 ].
← all excerpts
Optimization of Intra-Arterial Administration of Chemotherapeutic Agents for Glioblastoma in the F98-Fischer Glioma-Bearing Rat Model.
1
—
—